9 Endocrinology Headlines You Missed in June 2026

June was a very active month for endocrinology, with major US Food and Drug Administration (FDA) approvals and a pair of major conferences. The FDA granted clearance to new devices for type 1 diabetes (T1D) while the Endocrine Society (ENDO) Annual Meeting 2026 and the American Diabetes Association (ADA) Scientific Sessions 2026 brought with them a substantial number of major trials in obesity and type 2 diabetes (T2D).

Retatrutide, an investigative triple GLP-1/GIP/glucagon agonist, showed substantial improvements in both T2D and weight loss, while petrelintide resulted in significant weight loss without the gastrointestinal side effects of GLP-1 RAs. Meanwhile, a subanalysis of the CATALYST trial demonstrated mifepristone’s efficacy regardless of previous GLP-1 treatments.

With so much major data revealed over the course of the month, the HCPLive editorial team has collected 9 of the most impactful headlines from June 2026 you may have missed. Catch up on key clinician insights, major trial readouts, and more below:

FDA News

Teplizumab Receives Accelerated FDA Approval for Stage 3 T1D in Children

On June 12, the FDA granted accelerated approval to teplizumab (Tzield) to delay endogenous insulin decline in adolescent patients aged 8-17 years recently diagnosed with stage 3 T1D. The decision marks the first disease-modifying therapy to receive approval in this newly diagnosed population. Teplizumab received its first FDA approval in November of 2022 to delay the onset of stage 3 T1D in adults and children aged ≥8 years with stage 2 T1D – in April of 2026, this indication was expanded to include children aged ≥1 year.

FDA Clears First OTC Glucose Monitor for Children

Also on June 12, the FDA cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use in adolescent patients as young as 2 years without prior insulin use. This decision makes Stelo the first over-the-counter continuous glucose monitor (CGM) available for a pediatric population. The system is made up of a wearable sensor paired with a compatible smartphone application that allows for continuous glucose measurement, recording, analysis, and display.

FDA Approves Veligrotug-vvze for Thyroid Eye Disease

Announced by Viridian Therapeutics on June 26, the FDA approved veligrotug under the name Lumvoa for thyroid eye disease (TED) regardless of disease activity or duration. Based on data from the THRIVE and THRIVE-2 clinical trials, which investigated the intravenous insulin-like growth factor 1 receptor (IGF-1R) antagonist, the decision followed Breakthrough Therapy designation and was granted under Priority Review.

Trial Updates

TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo

Retatrutide, a GLP-1/GIP/glucagon receptor agonist in development by Eli Lilly, demonstrated significant A1c reduction and weight loss among patients with T2D in the TRANSCEND-T2D-1 trial. The phase 3 trial saw retatrutide recipients reach an average A1c reduction of ≤2% from a baseline of 7.9% while displaying a relatively tolerable adverse event rate.

TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight

Retatrutide went on a tear at ADA 2026, between TRANSCEND-T2D-1 and TRIUMPH-1. The latter showed the triple agonist’s efficacy in weight loss among patients with obesity, with patients on 9 and 12 mg of retatrutide losing an average of 64.4 lbs and 70.3 lbs, respectively. This staggering weight loss was accompanied by 65.3% of patients on the 12 mg dose achieving a BMI <30, below the minimum threshold for clinical obesity.

Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD

The VESPER-1 and VESPER-3 trials both highlighted the ultra-long-acting GLP-1 RA berobenatide’s potential in patients with obesity and overweight, with or without T2D. This particular drug is administered monthly, allowing for a potential departure from weekly injection schedules and an improvement in adherence and treatment cost. In an exclusive interview with HCPLive, John Buse, MD, PhD, discussed the data from these trials and how the investigative berobenatide could revolutionize weight loss.

Conference Insights

Diabetes Increases Mortality Risk Across All Major Organ Transplants

In an interview at ENDO 2026, Mishal Ali, a graduate researcher at the University of Chicago, and Alan Hutchison, MD, PhD, a clinical instructor of medicine and transplant hepatologist at the University of Chicago Medicine, discussed their recent study indicating that the presence of diabetes substantially increases long-term mortality across all major organ transplants. After examining patients receiving kidney, heart, lung, and liver transplants, Ali and Hutchison found a 6.8-fold variation in diabetes burden, concluding that a need for organ-specific prevention and management strategies exists.

Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment

A subanalysis of the CATALYST trial has indicated mifepristone’s capacity to improve HbA1c, weight, and waist circumference regardless of prior treatment with GLP-1 RAs in patients with poorly controlled T2D. During the analysis, the team found that these improvements were most pronounced among patients receiving tirzepatide, potentially signaling that patients with poorly controlled T2D may require further hypercortisolism screening.

ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial

The investigative human amylin analog petrelintide has demonstrated sustained weight loss in patients with obesity while maintaining high tolerability throughout the entire ZUPREME-1 trial. According to Timothy Garvey, MD, a professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, petrelintide also resulted in substantially lower gastrointestinal side effects compared to GLP-1-based therapies, particularly nausea.